3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Sarcoma
3
Pancreatic Neoplasms
3
Breast Neoplasms
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Brain Neoplasms
2
Wilms Tumor
1
Thrombocytosis
1
Sarcoma, Ewing
1
Recurrence
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Interventions
Peripheral Blood Stem Cell Transplantation
6
Cyclophosphamide
6
fludarabine phosphate
5
Nivolumab
5
Mycophenolic Acid
5
Carboplatin
5
Whole-Body Irradiation
4
Radiotherapy
4
Filgrastim
4
Cyclosporine
4
Gemcitabine
3
Cisplatin
3
Busulfan
3
Antilymphocyte Serum
3
cabozantinib
2
cabazitaxel
2
Voriconazole
2
Thiotepa
2
Therapeutics
2
Standard of Care
2
Sirolimus
2
Polymerase Chain Reaction
2
Mitomycin
2
Methylprednisolone
2
Methotrexate
2
Melphalan
2
Itraconazole
2
Immunoglobulin G
2
Goserelin
2
Flow Cytometry
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
entrectinib
×
Genitourinary
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA